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One of the major complications that limit the success of allogeneic stem cell transplantation is graft-versus-host
disease (GVHD). The major target organ in GVHD is the skin. Cutaneous GVHD can eventually lead to ﬁbrosis of the
skin. Fibronectin mediates a variety of cellular interactions with the extracellular matrix. The molecular and func-
tional diversity of ﬁbronectin (FN) arises from alternative splicing of pre-mRNA. In normal circumstances end-
othelial cells and ﬁbroblasts synthesize FN without the ED-A domain. In tissue repair and pathologic circumstances
such as ﬁbrosis, the ED-A domain is expressed. We hypothesize that expression of ED-A FN is upregulated in
patients with cutaneous GVHD. In frozen skin biopsies the expression of ED-A FN was measured at the protein level
by immunohistochemistry and at the mRNA level by quantitative real-time PCR (qPCR). In normal control skin,
immunohistochemistry showed slight deposits of ED-A FN just under the basal layer. The expression of ED-A FN
significantly increased in acute cutaneous GVHD (po0.05) and ED-A FN was strongly deposited in chronic cu-
taneous GVHD (po0.001). Quantitative PCR also showed increased expression of ED-A FN mRNA in acute and
chronic cutaneous GVHD compared with normal control skin (p¼ 0.07 and 0.039, respectively). The expression of
ED-A FN is increased in the skin of patients with cutaneous GVHD measured both with immunohistochemistry and
qPCR. ED-A FN is a new marker of ﬁbrosis in the skin of patients with cutaneous GVHD.
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Allogeneic stem cell transplantation (SCT) is an important
treatment option for many patients with hematological ma-
lignancies. One of the major complications that limit the
overall success of this treatment includes the development
of graft-versus-host disease (GVHD). GVHD can be divided
into acute GVHD, which may occur up to 100 d after trans-
plantation and chronic GVHD that continues from day 100
on. Acute GVHD can be divided into grades 0, I, II, III, and
IV, with grade IV being the most severe form and chronic
GVHD is graded as limited and extensive. Grading of GVHD
is diagnosed clinically and confirmed pathologically by skin
or mucosal biopsy and classified according to standard
criteria (Thomas et al, 1975).
The skin, liver, and gut are principally involved in GVHD,
with cutaneous GVHD being the most frequent manifesta-
tion both in acute and chronic GVHD. Cutaneous GVHD
includes inflammatory and/or fibrosing manifestations (Fe-
rrara and Deeg, 1991; Favre et al, 1997; Aractingi and
Chosidow, 1998). Cutaneous fibrosis is characterized by a
more permanent presence of connective tissue bearing
features of granulation tissue that results in excessive ex-
tracellular matrix (ECM) deposition and may result in the
deformation of soft tissue (Schurch et al, 1997). The fibrosis
in patients with sclerodermatous cutaneous GVHD leads to
severe disability. At present there are no early markers or
tools to objectify and monitor fibrosis, nor tools to predict
progression of fibrosis in cutaneous GVHD.
Fibronectin (FN), a 440 kDa dimeric glycoprotein, is an
adhesive extracellular matrix glycoprotein that plays crucial
roles in various cellular functions, including cell adhesion,
migration, proliferation, and differentiation. The domain
structure of FN consists of three internally homologous re-
peats, termed type I, II, and III and contains binding sites for
cell surface receptors and for other ECM components
(Petersen et al, 1983; Magnusson and Mosher, 1998). The
molecular diversity of FN arises from alternative splicing of
pre-messenger RNA (mRNA) at three variable regions ED-A,
ED-B, and IIICS. (Norton and Hynes, 1987) FN is biologically
classified into two forms, namely plasma FN and cellular
FN. Cellular FN is produced by fibroblasts, endothelial cells,
fat cells and to a lesser extent by hepatocytes, deposited in
tissues and generally insoluble. Only cellular FN contains
ED-A and ED-B domains.
Deposits of ED-A and ED-B FN isoforms are limited in
normal adult tissues but are dominantly expressed in em-
bryonic tissues and re-expressed in various reactive and
pathologic processes such as those found in wound heal-
ing, cardiac hypertrophy, diabetic nephropathy, breast, lung
Abbreviations: FN, fibronectin; GVHD, graft-versus-host disease;
QPCR, quantitative reverse transcriptase in real-time
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or liver tumors, liver fibrosis, and pulmonary fibrosis (Vartio
et al, 1987; Ffrench-Constant et al, 1989; Jarnagin et al,
1994). Uncontrolled differentiation of fibroblasts into my-
ofibroblasts has been suggested as the leading cause of
fibrotic diseases (Zhang et al, 1994). ED-A and transforming
growth factor (TGF)-b1, in the presence of mechanical
stress, are presently considered as the main inducers of
the myofibroblastic phenotype being able to upregulate a-
smooth muscle actin (a-SM actin) and collagen I expression
in fibroblasts (Desmouliere et al, 1993; Ronnov-Jessen and
Petersen, 1993; Vyalov et al, 1993b; Jarnagin et al, 1994;
Zhang et al, 1994; Serini et al, 1998).
We hypothesized an increased expression of ED-A FN in
patients with cutaneous GVHD. To assess whether ED-A FN
expression can differentiate between normal skin and the
different grades of acute and chronic cutaneous GVHD, we
evaluated the expression and localization of ED-A FN in
frozen skin biopsy specimens of patients with cutaneous
GVHD by immunohistochemistry. To gain further insight into
the dynamics of ED-A production we also studied the ex-
pression of ED-A FN at mRNA level by quantitative reverse




Normal skin. Immunohistochemistry showed slight depos-
its of ED-A FN just under the basal layer of the epidermis
and in the subendothelial matrix of the small vessels in the
upper dermis in seven of 10 control patients. No expression
was seen below the papillary dermis (Table S1 and Fig 1A).
Acute cutaneous GVHD. The expression of ED-A FN in-
creased in acute cutaneous GVHD. Deposits were found in
all sections in the upper stratum papillare, varying from
modest to severe staining. In all but one patient, expression
was found in the subendothelial matrix of the small vessels
in the upper dermis. Two patients showed moderate stain-
ing in the deep stratum papillare and six patients showed
deposits in the subendothelial matrix of the deeper vessels
(Table S2 and Fig 1B). Patients with grade I acute cutaneous
GVHD had less expression than patients with grade II acute
cutaneous GVHD, although not significant (p¼ 0.36).
Chronic cutaneous GVHD. Immunohistochemistry showed
strong depositions of ED-A FN. All patients had expression
in the upper papillary dermis and in the subendothelial ma-
trix of the small vessels in the upper dermis. Five patients
showed deposits in the deep stratum papillare, four patients
in the upper stratum reticulare, eight patients in the sub-
endothelial matrix of the small vessels in the lower dermis,
four patients in the deeper stratum reticulare and one patient
in the subcutis (Table S3 and Fig 1C). The patients with
limited chronic cutaneous GVHD had more superficial stain-
ing of ED-A FN, whereas the patients with extensive chronic
cutaneous GVHD had also depositions of ED-A FN in the
deeper layers of the dermis. Patients with extensive chronic
cutaneous GVHD had significantly more ED-A FN staining
than the patients with limited chronic cutaneous GVHD
(p¼ 0.023).
Skin layers. The Kruskal–Wallis test showed significant dif-
ferences between normal skin, acute and chronic cutane-
ous skin when all skin layers were combined and in the
different layers separately, except for the subcutis (Table
S4). Pairwise comparisons of the effect between each pair
of groups showed a significant difference between normal
skin and acute cutaneous GVHD skin in the upper stratum
papillare. We observed a significant difference between
normal skin and chronic cutaneous GVHD skin in the su-
perficial vasculature. The deep vasculature and all layers
Figure1
ED-A fibronectin (FN) staining of normal, acute and chronic cuta-
neous graft-versus-host-disease (GVHD) skin biopsies. (A) ED-A FN
staining of normal skin showing weak positivity in the subendothelial
matrix of the upper vascular endothelial cells. (B) ED-A FN staining of
acute cutaneous GVHD skin showing strong positivity in the sub-
endothelial matrix of the upper vascular endothelial cells and in the
stratum papillare. (C) ED-A FN staining of chronic cutaneous GVHD
skin showing extensive positivity in the subendothelial matrix of the
upper and lower vascular endothelial cells and in the deeper layers of
the dermis. Original magnification 100 (A–C).
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together showed a significant difference between normal
skin and acute and chronic cutaneous GVHD, respectively.
The deep stratum papillare, the upper stratum reticulare and
the deep stratum reticulare showed no pairwise significance
(Table S4).
The epidermal layer did not show staining of ED-A FN in
any of the sections, neither in normal controls, nor in pa-
tients with acute or chronic cutaneous GVHD.
Total FN staining Total FN was abundantly expressed in all
sections. No differences in staining could be observed be-
tween normal control skin, acute cutaneous GVHD and
chronic cutaneous GVHD skin (data not shown).
Sirius red staining The collagen bundles were most en-
larged in patients with chronic cutaneous GVHD, enlarged in
patients with acute cutaneous GVHD and not enlarged
in normal skin biopsies.
Inﬂammation markers The infiltrate of the acute and chronic
cutaneous GVHD skin biopsies consisted mainly of CD3þ
cells with the predominant expression of CD4þ with sparse
CD8þ cells. No difference was seen between the acute
and chronic skin biopsies, no infiltrates were seen in the
normal control biopsies.
Quantitative PCR We analyzed the 1/(EDAþ (FN with the
ED-A fragment)/EDA (FN without the ED-A fragment)) ratio
in normal (n¼ 10), acute cutaneous (n¼10) and chronic
cutaneous (n¼10) skin biopsies by qPCR. We observed an
increased ratio in acute and chronic cutaneous GVHD com-
pared with normal control skin (p¼0.07 and 0.039, respec-
tively, Fig 2). The highest 1/(EDAþ /EDA) ratio was found
in skin biopsies with acute cutaneous GVHD (Fig 2).
Discussion
The expression of ED-A FN is increased in the skin of
patients with cutaneous GVHD measured both with im-
munohistochemistry and qPCR. Immunohistochemistry
showed slight deposits of ED-A FN in normal control skin.
The staining was only present in the stratum papillare and
the subendothelial matrix of the upper vessels. The expres-
sion increased in patients with acute cutaneous GVHD. All
patients showed depositions in the superficial layer of the
dermis. Six patients had expression of the deeper small
vessels. Chronic cutaneous GVHD showed similar expres-
sion of ED-A FN in the superficial layer and by far the
strongest expression of ED-A FN in the deeper layers of the
dermis. By Kruskal–Wallis statistics and Dunn’s multiple
comparison test we found the most significant increase in
expression of ED-A FN in chronic GVHD sections of the
superficial vasculature, the deep vasculature and when all
layers were combined. In patients with acute cutaneous
GVHD there was a significantly increased expression of
ED-A FN in the stratum papillare. Patients with grade I
acute cutaneous GVHD appeared to have less ex-
presmshy;sion than patients with grade II acute cutaneous
GVHD, although this was not significant (p¼0.36). Nine-
teen of 20 patients received T cell depletion, therefore,
none of the patients developed severe grade III or IV acute
GVHD.
One may speculate that the development of a higher
grade of acute GVHD gives more expression of ED-A FN
and that patients who will develop chronic GVHD have al-
ready an increased expression of ED-A FN even during
acute GVHD. Patients with extensive chronic GVHD devel-
oped more expression in the deeper layers and more dep-
osition of ED-A FN compared with patients with limited
chronic GVHD (p¼0.023).
The routine measurements for inflammation markers
were typical for cutaneous GVHD. No infiltrates were seen
in the normal control biopsies and infiltrates with the ma-
jority of CD3þ cells; predominantly expressing CD4þ cells
were seen in the acute and chronic cutaneous GVHD biop-
sies. The routine measurements for collagen bundles
showed similar results for the Sirius Red staining and the
ED-A FN staining. So, a correlation between collagen syn-
thesis and ED-A FN is likely to occur.
Quantitative PCR analysis showed a significant differ-
ence in the 1/(EDAþ /EDA) ratio between normal control
skin and chronic cutaneous GVHD (p¼0.039) and a trend
between normal control skin and acute cutaneous GVHD
(p¼0.07), meaning that relatively more ED-A FN mRNA was
formed in the acute and chronic cutaneous GVHD biopsies.
No difference was found in the 1/(EDAþ /EDA) ratio be-
tween the different grades of acute cutaneous GVHD or
between patients who developed limited or extensive dis-
ease for chronic cutaneous GVHD. The borderline signifi-
cance for the Taqman analysis between normal control skin
and acute cutaneous GVHD might be caused by the use of
whole skin biopsies, not discriminating between the layers
in the skin for the qPCR analysis. Further studies should
focus on the different skin layers. Another explanation
can be that the expression of mRNA EDAþ FN rises rapidly
in early stages of acute cutaneous GVHD as an acute
Figure 2
EDAþ fibronectin (FN) and EDA FN mRNA quantification com-
paring normal (n¼10) with acute graft-versus-host disease (GVHD)
(n¼ 10) and chronic GVHD (n¼ 10) skin biopsies, respectively.
mRNAs were quantified using qPCR of cDNA. Results are expressed as
1 divided by the ratio of the threshold cycle (Ct) of EDAþ FN divided by
the Ct of EDA FN: 1/(EDAþ /EDA). Threshold cycles were stand-
ardized by Ct for the housekeeping gene PBGD. The ratio increases
when relatively more EDAþ copies are formed. The 1/ (EDAþ /EDA)
ratio of both acute and chronic cutaneous GVHD were compared with
normal skin, thereby taking the latter as the reference group. p values
arefrom Student’s t test.
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phase reaction and returns to lower levels in time, except
in patients who eventually develop chronic cutaneous
GVHD.
FN plays important roles in the development of fibro-
genesis (Vartio et al, 1987; Ffrench-Constant et al, 1989;
Jarnagin et al, 1994; Ting et al, 2000). Fibrosis is the pro-
duction of fibrous connective tissues as a consequence of
chronic inflammation or healing. Its function is to replace
lost parenchymal tissue (Schurch et al, 1997). In cutaneous
GVHD, fibrosis will be caused by chronic inflammation (Fe-
rrara and Deeg, 1991). During fibrosis fibroblasts change
into myofibroblast under the influence of ED-A FN and TGF-
b1. TGF-b1 precedes the expression of ED-A FN (Des-
mouliere et al, 1993; Ronnov-Jessen and Petersen, 1993;
Serini et al, 1998). It is an important cytokine produced by
monocytes/macrophages that are activated by the condi-
tioning regimen preceeding the transplantation (Khalil et al,
1989, 1993; Vyalov et al, 1993a; Xing et al, 1997). Cutaneous
GVHD is caused by donor T cells reacting against the end-
othelial and epithelial cells of the patients causing an influx
of inflammatory cells in the skin, such as macrophages that
are able to produce TGF-b1 (Favre et al, 1997; Aractingi and
Chosidow, 1998). TGF-b1 activates resident fibroblastic
cells to synthesize ED-A FN and they both induce the my-
ofibroblastic phenotype by upregulating a-SM actin and
collagen I expression (Desmouliere et al, 1993; Ronnov-
Jessen and Petersen, 1993; Vyalov et al, 1993b; Jarnagin
et al, 1994; Zhang et al, 1994; Serini et al, 1998).
As far as we know, this is the first study, in which the
expression of ED-A FN is studied in the skin of patients with
cutaneous GVHD. Overexpression of ED-A FN has been
reported in the dermal–epidermal junction of the skin in pa-
tients with psoriasis, although absent in the skin from con-
trol subjects (Ting et al, 2000), and overexpression has also
been reported in Dupuytren’s disease (Halliday et al, 1994;
Berndt et al, 1995). At the moment we are investigating the
expression of ED-A FN in skin biopsies taken from patients
with systemic sclerosis. Furthermore, blood samples will be
analyzed for ED-A FN levels in patients with cutaneous
GVHD (Kanters et al, 2001).
The expression of ED-A FN appeared to be an important
marker of fibrosis in the skin following immunohistochem-
ical staining. Expression of ED-A FN in the deeper layers of
the skin was specific for chronic cutaneous GVHD. As no
practical tools are available to objectify fibrosis in cutane-
ous GVHD at the moment, it would be interesting to inves-
tigate more skin biopsies with qPCR. This is in order to see
if it is possible, by means of the 1/(EDAþ /EDA) ratio, to
objectify the grade of acute cutaneous GVHD and to predict
which patients eventually will develop chronic cutaneous
GVHD. We plan to perform prospective studies in order to
further investigate the use of detection of EDAþ versus ED-A
FN by qPCR in classifying the grade of acute cutaneous
GVHD as well as in evaluating its possible prognostic value.
In these studies laser microdissection will be applied to
differentiate between ED-A FN mRNA expression in the
different layers.
We conclude that ED-A FN is a new marker of fibrosis in
the skin of patients with cutaneous GVHD and can be of
great potential in future for detection, prediction and im-
provement of therapy.
Material and Methods
Patients A total of twenty 3 mm punch biopsy specimens of skin
were obtained from 20 allogeneic bone marrow recipients (14 male
and six female) with acute cutaneous GVHD (n¼ 10) between day
12 and day 26 after transplantation and with chronic cutaneous
GVHD (n¼ 10) between 150 d and 123 mo after transplantation.
The underlying disease was chronic myeloid leukemia (CML) in 7
patients, multiple myeloma in five patients, acute myeloid leukemia
(AML) in four patients, acute lymphoid leukemia (ALL) in two pa-
tients and non-Hodgkin lymphoma (NHL) in two patients. The mean
age at transplantation was 44 y (range 24–55). Pre-transplant
conditioning regimens consisted of cyclophosfamide (60 mg per
kg) and total-body irradiation (TBI) in 16 patients, of antithymocyte
globulin (ATG), cyclophosfamide and TBI in three patients, and of
Fludarubine and TBI in 1 patient. Nineteen patients treated with
myeloablative cyclophosphamide plus TBI (and ATG) received
partial T cell-depleted stem cell grafts consisting of 1–2  105 T
cells per kg (Verdonck et al, 1990) and the one patient receiving
non-myeloablative Fludarabine plus low-dose TBI got a full stem
cell graft (i.e., a non-manipulated graft). Cyclosporine was given as
prophylaxis for GVHD. Donors were human leukocyte antigen
(HLA)-matched sibs for 17 cases, 1 HLA-locus mismatched for one
case, and two were HLA-matched unrelated.
Control biopsy specimens of skin were obtained from 10
healthy controls. Written informed consent for biopsies was ob-
tained from all patients and the institutional review board approved
the protocol. The study was conducted according to the Decla-
ration of the Helsinki Principles.
Skin biopsies and histological examination Following trans-
plantation all 20 patients were biopsied at the site of maximal in-
volvement within 4 d of presentation. The 3 mm punch biopsies
were taken before any therapy for GVHD was given. The speci-
mens were divided in two parts. One was formalin-fixed for routine
histological examination; the other part was immediately frozen in
liquid nitrogen for immunohistochemical analysis. Histological di-
agnosis of acute and chronic cutaneous GVHD was made and
graded according to the Seattle criteria. (Thomas et al, 1975).
Immunohistochemistry Biopsies were cut into 6 mm sections on
a freezing microtome and mounted on coated slides or used for the
isolation of mRNA for the qPCR.
Cryostat sections were immunostained by the indirect immu-
noperoxidase method using the following antibodies: monoclonal
Mouse Anti-cellular Fibronectin (ED-A domain) (ICN Biomedicals,
Costa Mesa, California) and polyclonal Rabbit Anti-Human Fibro-
nectin (Dako, Glostrup, Denmark). As second and third steps,
sections were incubated with peroxidase-conjugated rabbit anti-
mouse immunoglobulin (DAKO-P260) or swine anti-rabbit immuno-
globulin (DAKO-E0431), then with peroxidase-conjugated swine
anti-rabbit immunoglobulin (DAKO-E0431) or peroxidase-conju-
gated rabbit anti-sheep immunoglobulin (DAKO-P0163). The per-
oxidase labelling was visualized using 3-amino-9-ethylcarbazole
(AEC, Sigma, St. Louis, Missouri) as substrate, resulting in red
staining. Slides were counterstained with hematoxylin.
Immunohistochemically stained skin sections were examined
by an independent observer (a pathologist) in the absence of clin-
ical information by light microscopy. ED-A FN staining was meas-
ured in the following dermal layers: the upper stratum papillare,
superficial vasculature, the deep stratum papillare, the upper stra-
tum reticulare, the deep vasculature, the deep stratum reticulare
and the subcutis. The labelling index, which was based essentially
on labelling intensity, was graded on a scale of 0–3 (0¼ no staining,
1¼mild staining, 2¼moderate staining and 3¼ severe staining).
Of all biopsies at least two sections were stained and scored.
As routine measurements, all biopsies have also been stained
by Sirius Red and for markers of inflammation. The skin biop-
sies were fixated in formalin and the slides were stained with
hematoxylin and eosin (H&E), Sirius red, CD3, CD4, and CD8.
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The H&E-stained slides were scored on the presence of a lymph-
ocytic infiltrate. The degree of the dermal sclerosis was scored in
the Sirius red stain, in which the thickness of collagen bundles can
be measured. The CD3, CD4 and CD8 (T cells) immunohistochem-
ical stainings were used to define the composition of the lymph-
ocytic infiltrate.
Isolatation of RNA and cDNA synthesis Total RNA of snap fro-
zen skin biopsies was isolated using an RNA-isolation kit (Qiagen,
Rneasy, Valencia, California). Isolation was made following the in-
structions of the company. Ribosomal RNAs (28S rRNA and 18S
rRNA) were visualized on a 1.0% agarose gel following RNA iso-
lation to demonstrate the integrity of the RNAs. One nanogram of
RNA was used for cDNA synthesis. cDNA synthesis was performed
with Superscript II RNase H Reverse Transcriptase (Life Technol-
ogies, Breda, The Netherlands) according to the manufacturer’s
instructions. Oligo (dT)1218 primers (Life Technologies) were used
as primers. Samples were stored at 201C until use. CopyDNA
was used for quantitative real-time PCR (qPCR).
Quantitative PCR Duplicate PCR samples (25 mL) were set up
with 2 mL cDNA, 5 mL buffer A 10  PCR buffer (Applied Biosys-
tems, Foster City, California), 2.5 mL 25 mM MgCl2 (Applied Bio-
systems), 2 mL 12.5 mM dNTPs (Applied Biosystems), 0.75 mL
primer mix (7.5 pmol each), 0.5 mL probe (5 pmol), and 0.15 mL
AmpliTaq Gold 5 U per mL and 12.1 mL milliQ water. The probes
were labelled at the 50 end with the reporter dye molecule 6-car-
boxy-fluorescein FAM and VIC for the ED-A FN and porphobilino-
gen deaminase (PBGD) probes, respectively, and at the 30 end
with the quencher dye molecule 6-carboxytertramethylrhodamine
(TAMRA). Amplification and detection were performed with an ABI
Prism 7700 sequence detection system (ABI/PE, Foster City, Cal-
ifornia) under the following conditions: 10 min at 951C to activate
AmpliTaq Gold DNA polymerase and 45 cycles of 15 s at 951C and
1 min at 601C. PBGD was included as PCR control for reaction on
cDNA and is considered as a housekeeping gene of which the
mRNA was measured to correct for variable cDNA input. As neg-
ative control, cDNA was replaced by MilliQ water.
Sequence of PCR primers and sequence-specific probes for
EDAþ or EDA and PBGD are seen in Table S5 and Fig 3. The
specificity and efficiency of both primer sets were tested on
plasmids containing the EDAþ or the EDA fragment.
We measured the differences in mRNA expression as 1 divided
by the ratio of the threshold cycle (Ct) (Heid et al, 1996) of EDAþ
divided by the Ct of EDA: 1/(EDAþ /EDA). The ratio is increased
when comparatively more EDAþ FN is formed. Threshold cycles
were standardized by Ct for PBGD.
Statistical analysis The 1/(EDAþ /EDA) ratio of both acute and
chronic cutaneous GVHD were compared with normal skin, there-
by taking the latter as the reference group. The p values were
emerged from Student’s t test. The Kruskal–Wallis test was used to
compare ED-A FN staining between normal skin, acute and chron-
ic cutaneous skin in different layers of the skin. If a significant
difference among the three groups was detected, pairwise com-
parisons were carried out by Dunn’s multiple comparison test to
investigate the nature of the effect between each pair of groups.
The Mann–Whitney test was used to compare clinical grade I with
grade II acute cutaneous GVHD and to compare limited with
extensive disease in chronic cutaneous GVHD. p values o0.05
were considered significant.
We wish to thank Wiebe R. Pestman (Centre for Biostatistics, Faculty of
Biology, Utrecht University) for expert statistical assistance.
Supplementary Material
The following material is available from http://www.blackwellpublishing.
com/products/journals/suppmat/JID/JID23474/JID23474sm.htm
Table S1. Histological ﬁndings of ED-A FN (ﬁbronectin) staining in
skin biopsies from normal controls
Table S2. Histological ﬁndings of ED-A FN (ﬁbronectin) staining
in skin biopsies with acute cutaneous GVHD (graft-versus-host
disease)
Table S3. Histological ﬁndings of ED-A-FN (ﬁbronectin) in skin bi-
opsies with chronic cutaneous GVHD (graft-versus-host disease)
Table S4. Kruskal–Wallis test and Dunn’s Multiple Comparison
Test for immunohistochemical staining of ED-A FN (ﬁbronectin)
Table S5. Sequence of PCR primers and specific probes for dif-
ferent targets
DOI: 10.1111/j.0022-202X.2004.23474.x
Manuscript received March 2, 2004; revised June 17, 2004; accepted
for publication June 17, 2004
Address correspondence to: Rob Fijnheer, Department of Haematol-
ogy, #G03.647, University Medical Center Utrecht, Heidelberglaan 100,
3584 CX Utrecht, The Netherlands. Email: r.fijnheer@azu.nl
References
Aractingi S, Chosidow O: Cutaneous graft-versus-host disease. Arch Dermatol
134:602–612, 1998
Berndt A, Kosmehl H, Mandel U, et al: TGF beta and bFGF synthesis and lo-
calization in Dupuytren’s disease (nodular palmar fibromatosis) relative to
cellular activity, myofibroblast phenotype and oncofetal variants of fibro-
nectin. Histochem J 27:1014–1020, 1995
Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G: Transforming growth factor-
beta 1 induces alpha-smooth muscle actin expression in granulation tis-
sue myofibroblasts and in quiescent and growing cultured fibroblasts.
J Cell Biol 122:103–111, 1993
Favre A, Cerri A, Bacigalupo A, Lanino E, Berti E, Grossi CE: Immunohisto-
chemical study of skin lesions in acute and chronic graft versus host
disease following bone marrow transplantation. Am J Surg Pathol 21:
23–34, 1997
Ferrara JL, Deeg HJ: Graft-versus-host disease. N Engl J Med 324:667–674,
1991
Ffrench-Constant C, Van de WL, Dvorak HF, Hynes RO: Reappearance of an
embryonic pattern of fibronectin splicing during wound healing in the
adult rat. J Cell Biol 109:903–914, 1989
Halliday NL, Rayan GM, Zardi L, Tomasek JJ: Distribution of ED-A and ED-B
containing fibronectin isoforms in Dupuytren’s disease. J Hand Surg [Am]
19:428–434, 1994
Heid CA, Stevens J, Livak KJ, Williams PM: Real time quantitative PCR. Genome
Res 6:986–994, 1996
Jarnagin WR, Rockey DC, Koteliansky VE, Wang SS, Bissell DM: Expression
of variant fibronectins in wound healing: Cellular source and biological
activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 127:
2037–2048, 1994
Figure 3
Primers and probes of EDAþ and EDA fibron-
ectin (FN). The forward primer of EDAþFN lies
within the EDA region, whereas the forward primer
of the EDA-FN does not include the EDA region. The
reverse primers and probes are similar for EDAþ
and EDA.
DETECTION OF FIBROSIS IN CUTANEOUS GVHD 1061123 : 6 DECEMBER 2004
Kanters SD, Banga JD, Algra A, Frijns RC, Beutler JJ, Fijnheer R: Plasma levels of
cellular fibronectin in diabetes. Diabetes Care 24:323–327, 2001
Khalil N, Bereznay O, Sporn M, Greenberg AH: Macrophage production of trans-
forming growth factor beta and fibroblast collagen synthesis in chronic
pulmonary inflammation. J Exp Med 170:727–737, 1989
Khalil N, Whitman C, Zuo L, Danielpour D, Greenberg A: Regulation of alveolar
macrophage transforming growth factor-beta secretion by cortico-
steroids in bleomycin-induced pulmonary inflammation in the rat. J Clin
Invest 92:1812–1818, 1993
Magnusson MK, Mosher DF: Fibronectin: Structure, assembly, and cardiovas-
cular implications. Arterioscler Thromb Vasc Biol 18:1363–1370, 1998
Norton PA, Hynes RO: Alternative splicing of chicken fibronectin in embryos and
in normal and transformed cells. Mol Cell Biol 7:4297–4307, 1987
Petersen TE, Thogersen HC, Skorstengaard K, Vibe-Pedersen K, Sahl P, Sottrup-
Jensen L, Magnusson S: Partial primary structure of bovine plasma fibro-
nectin: Three types of internal homology. Proc Natl Acad Sci USA 80:
137–141, 1983
Ronnov-Jessen L, Petersen OW: Induction of alpha-smooth muscle actin by
transforming growth factor-beta 1 in quiescent human breast gland fibro-
blasts. Implications for myofibroblast generation in breast neoplasia. Lab
Invest 68:696–707, 1993
Schurch W, Seemayer TA, Gabbiani G, Sternberg SS, (ed). Histology for Pathol-
ogists. New York: Raven Press, 1997; p 129–165
Serini G, Bochaton-Piallat ML, Ropraz P, Geinoz A, Borsi L, Zardi L, Gabbiani G:
The fibronectin domain ED-A is crucial for myofibroblastic phenotype
induction by transforming growth factor-beta1. J Cell Biol 142:873–881,
1998
Thomas ED, Storb R, Clift RA, et al: Bone-marrow transplantation (second of two
parts). N Engl J Med 292:895–902, 1975
Ting KM, Rothaupt D, McCormick TS, et al: Overexpression of the oncofetal Fn
variant containing the EDA splice-in segment in the dermal–epidermal
junction of psoriatic uninvolved skin. J Invest Dermatol 114:706–711,
2000
Vartio T, Laitinen L, Narvanen O, Cutolo M, Thornell LE, Zardi L, Virtanen I: Dif-
ferential expression of the ED sequence-containing form of cellular
fibronectin in embryonic and adult human tissues. J Cell Sci 88 (Pt 4):
419–430, 1987
Verdonck LF, de Gast GC, van Heugten HG, Dekker AW: A fixed low number of
T-cells in HLA-identical allogeneic bone marrow transplantation. Blood
75:776–780, 1990
Vyalov S, Desmouliere A, Gabbiani G: GM-CSF-induced granulation tissue for-
mation: Relationships between macrophage and myofibroblast accumu-
lation. Virchows Arch B Cell Pathol Incl Mol Pathol 63:231–239, 1993a
Vyalov SL, Gabbiani G, Kapanci Y: Rat alveolar myofibroblasts acquire alpha-
smooth muscle actin expression during bleomycin-induced pulmonary
fibrosis. Am J Pathol 143:1754–1765, 1993b
Xing Z, Tremblay GM, Sime PJ, Gauldie J: Overexpression of granulocyte-ma-
crophage colony-stimulating factor induces pulmonary granulation tissue
formation and fibrosis by induction of transforming growth factor-beta 1
and myofibroblast accumulation. Am J Pathol 150:59–66, 1997
Zhang K, Rekhter MD, Gordon D, Phan SH: Myofibroblasts and their role in lung
collagen gene expression during pulmonary fibrosis. A combined immuno-
histochemical and in situ hybridization study. Am J Pathol 145:114–125,
1994
1062 VAN DER STRAATEN ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
